{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73","upperLimit":"82","value":"78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"396"}],"units":"Participants"}],"description":"Proportion of basal subtype was calculated as number of patients who had basal subtype disease divided by all triple-negative breast cancers who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who were randomized to arms B and C after 6/22/2016 (when arm C was open to accrual). Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized regardless of their intrinsic subtype. Proportion of basal subtype was calculated in patients randomized after 6/22/2016.","id":"OG000","title":"All Patients Concurrently Randomized to Arms B and C"}],"paramType":"NUMBER","populationDescription":"Analysis population was all patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results. Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized to arms B and C regardless of their intrinsic subtype. Proportion of basal subtype was calculated in the 396 patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype assay results at the final analysis time.","reportingStatus":"POSTED","timeFrame":"Assessed at registration to step 0 (baseline)","title":"Proportion of Basal Subtype","type":"SECONDARY","unitOfMeasure":"percentage of participants"}